CHOLESTEROL: PCSK9 INHIBITORS FOR FAMILIAL HYPERCHOLESTEROLEMIANG, KELVINMeducator
Combination of cholesterol absorption inhibitors and/or PCSK9 inhibitors should be considered when LDL-C targets are not met after statin therapy. Early use of PCSK9 monoclonal antibodies has been shown to reduce ASCVD risk earlier and more significantly, with good safety for prolonged use (≥7 y...
De Vergori V., Gomaraschi M., Mombelli G., Pazzucconi F., Zacherl C., et al. Hypocholesterolaemic effects of lupin protein and pea protein/fibre combinations in moderately hypercholesterolaemic individuals. Br. J. Nutr. 2011;107:1176–1183. ...
4. M. S. Sabatine, PCSK9 inhibitors: Clinical evidence and implementation.Nat. Rev. Cardiol. 16, 155–165 (2018).5. K. K. Ray, R. S. Wright, D. Kallend et al. ORION-10 and ORION-11 Investigators, Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol.N. E...
10. Koskinas, K. C. et al. Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and ...
[5] Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment.[J] .J Med Chem, 2022, 65: 15513-15539.
[13]Matta A, et al. Ineffective Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Monotherapy in Dyslipidemia with Low-Density Lipoprotein Cholesterol (LDL-C) ReceptorAbnormalities: A Report of 2 Cases. Am J Case Rep. 2020;21:e923722. [14]Thedrez A, et al. Homozygous familial hypercholesterolemia ...
6. Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol, 2019, 16(3):155-165. 7. Libby P, Tokgözoğlu L.Chasing LDL cholesterol to the bottom—PCSK9 in perspective. Nat Cardiovasc Res, 2022, 1: 554-561....
Although therapeutic PCSK9 inhibition could theoretically have undesired effects by interfering with these non-cholesterol-related processes, studies of individuals with genetically determined reduced PCSK9 function and clinical trials of PCSK9 inhibitors have not revealed clinically meaningful adverse ...
While relatively high cost can be given as a problem, PCSK9 inhibitors are able to reduce LDL cholesterol dramatically even in FH patients who could not achieve targets until now. To ensure that these drugs are given to the patients who really need them, it is necessary to raise the ...